Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986340 plus nivolumab biomarker study in metastatic solid tumors
2025-524125-40-01Phase 2Authorised
- Sponsor
- Humanitas Research Hospital
- Start
- Jul 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab and imzokitug in non-small cell lung cancer (NSCLC), gastric adenocarcinoma, colorectal cancer (CRC) and 1 more (4 cohorts), sponsored by Humanitas Research Hospital. Primary endpoints: Biomarker identification and Disease control rate. Planned start Jul 2026; status: authorised.
02
Drugs
nivolumabimzokitug
03
Conditions
non-small cell lung cancer (NSCLC)gastric adenocarcinomacolorectal cancer (CRC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2025-524125-40-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524125-40-01.